Details for New Drug Application (NDA): 203466
✉ Email this page to a colleague
The generic ingredient in CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE is candesartan cilexetil; hydrochlorothiazide. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.
Summary for 203466
| Tradename: | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE |
| Applicant: | Zydus Lifesciences |
| Ingredient: | candesartan cilexetil; hydrochlorothiazide |
| Patents: | 0 |
Pharmacology for NDA: 203466
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
| Physiological Effect | Increased Diuresis |
Suppliers and Packaging for NDA: 203466
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | candesartan cilexetil; hydrochlorothiazide | TABLET;ORAL | 203466 | ANDA | Zydus Lifesciences Limited | 70771-1325 | 70771-1325-0 | 1000 TABLET in 1 BOTTLE (70771-1325-0) |
| CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | candesartan cilexetil; hydrochlorothiazide | TABLET;ORAL | 203466 | ANDA | Zydus Lifesciences Limited | 70771-1325 | 70771-1325-1 | 100 TABLET in 1 BOTTLE (70771-1325-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 16MG;12.5MG | ||||
| Approval Date: | Nov 27, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 32MG;12.5MG | ||||
| Approval Date: | Nov 27, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 32MG;25MG | ||||
| Approval Date: | Nov 27, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
